Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus ORAGRAFIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus ORAGRAFIN CALCIUM.
HYPAQUE-CYSTO vs ORAGRAFIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Oragrafin Calcium is a diagnostic radiocontrast agent that contains calcium ipodate. It acts by absorbing X-rays due to its high iodine content (61% iodine by weight). After oral administration, it is absorbed and excreted into the bile, allowing radiographic visualization of the gallbladder and biliary ducts. It may also enhance CT imaging of the liver and biliary tree.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Oral: 5 mL (1 packet) orally, may repeat in 30-60 minutes if needed. Maximum 2 doses per procedure. Rectal: 100-200 mL of a 1:1 dilution with water as a retention enema.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life is 1.2 hours (0.7–2.0 hours) in patients with normal renal function. May be prolonged in renal impairment (up to 18 hours in severe impairment).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Primarily renal: 90% of absorbed dose excreted unchanged in urine within 24 hours; <10% via feces. Biliary excretion is negligible in the absence of hepatobiliary obstruction.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent